David P. Meeker, M.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About David P. Meeker, M.D.
David P. Meeker, M.D. is recorded as Chairman and CEO at Rhythm Pharmaceuticals, Inc. (RYTM). The proxy statement of Rhythm Pharmaceuticals, Inc. reports total compensation of $17,544,525 for David P. Meeker, M.D. in fiscal 2025, including a base salary of $807,692. Disclosed compensation is on record for 6 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2020-07-20–present
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Rhythm Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Hunter Smith CEO, CFO
- David Meeker Chairman
- Christophe R. Jean Board Member
- David W. J. McGirr Board Member
- Jennifer Good Board Member
- Kimberly J. Popovits Board Member
- Lynn A. Tetrault Board Member
- Stuart A. Arbuckle Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $807,692 | $17,544,525 |
| 2024 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $740,472 | $14,663,742 |
| 2023 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $704,715 | $7,230,457 |
| 2022 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $652,050 | $3,325,758 |
| 2021 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $630,000 | $6,458,360 |
| 2020 | Rhythm Pharmaceuticals, Inc. (RYTM) | Chief Executive Officer | $262,308 | $14,277,367 |
Recent activity
No call appearances or filed executive changes recorded yet.